Power to the Patients podcast

Precision Medicine Got Kidney Disease Wrong—Until Now

0:00
42:13
Rewind 15 seconds
Fast Forward 15 seconds
Explore how variant functionalization is driving the future of mechanism-driven medicines as host Brandon interviews Jason Coloma, CEO of Maze Therapeutics, on Power to the Patients. Jason explains why most gene-disease associations fail to become therapies, how APOL1-mediated kidney disease reveals the power of precision nephrology, and what it actually takes to build an integrated genetics-to-drug-discovery platform.

More episodes from "Power to the Patients"